DexCom's not just a diabetes company anymore. They're at the forefront of wearable health tech, blurring the lines between medicine and lifestyle. DexCom might not be the flashiest stock, but their ...
Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...
DexCom's growth rate has been declining over multiple periods. The company expects as little as 1% organic growth for the current quarter. Investors may see this as proof that GLP-1 drugs are ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...
In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 ...
DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results